Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoeconomics
Hauptverfasser: Blommestein, Hedwig M., Armstrong, Nigel, Ryder, Steve, Deshpande, Sohan, Worthy, Gill, Noake, Caro, Riemsma, Rob, Kleijnen, Jos, Severens, Johan L., Al, Maiwenn J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2015
Schlagworte:
Review Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4706836/
https://ncbi.nlm.nih.gov/pubmed/26314282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0318-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge